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Abstract
Warfarin is an oral anticoagulant that requires frequent therapeutic drug 
monitoring due to a narrow therapeutic window, considerable interindividual 
variability in drug response, and susceptibility to drug-drug and drug-diet 
interactions. Enantiomeric separation and quantification of warfarin enantiomers 
and clinically important major hydroxylation metabolites are essential for drug 
interaction studies and phenotypic characterization of CYP2C9 and CYP3A4, 
the major Cytochrome P450 (CYP) enzymes involved in warfarin metabolism. 
Here, we describe the development and validation of a chiral high performance 
liquid chromatography-tandem mass spectrometry (HPLC-MS/MS)-based 
quantification of R-warfarin, S-warfarin, S-7-hydroxywarfarin (the major 
CYP2C9metabolite) and (9R; 10S)-10-hydroxywarfarin (the CYP3A4 metabolite) 
in human plasma. Simple protein precipitation-based extraction showed good 
recovery of analytes (82.9 - 96.9%). The developed method exhibited satisfactory 
intra-day and inter-day accuracy and precision. The lower limits of detection 
were 0.25nM (or ~0.08 ng/ml) for the warfarin enantiomers and 0.1nM (or ~0.04 
ng/mL) for S-7-hydroxywarfarinand (9R; 10S)-10-hydroxywarfarin using only 
50μL plasma during extraction. The validated method was successfully applied 
to analyze plasma samples obtained from a healthy human subject who enrolled 
in a clinical drug interaction study involving warfarin.
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maintain optimal anticoagulant activity: warfarin efficacy is frequently 
monitored by the prothrombin time (PT) or the Internationally 
Normalized Ratio (INR). Despite target INR monitoring and careful 
dose adjustment: the rate of warfarin-related bleeding events has not 
diminished [3,4]. Genetic factors including VKORC1: concomitant 
drugs/diet: and various disease states can impact on the efficacy of 
warfarin by changing its pharmacokinetics. Thus: sensitive and 
specific analytical methods to quantify warfarin and its clinically 
significant metabolites in various matrices: especially human plasma: 
may help to improve the understanding of warfarin pharmacology 
and detection of potential warfarin-drug/diet interactions.
Warfarin is a racemic mixture of R- and S-enantiomers. S-warfarin 
is more potent (3-5 times) pharmacologically than R-warfarin [5]: 
however S-warfarin clearance is greater than that of R-warfarin. Both 
enantiomers undergo extensive cytochrome P450 (CYP)-mediated 
metabolism in the liver. CYP2C9 catalyzes the 6- and 7-hydroxylation 
of S-warfarin: with S-7-hydroxywarfarin (S-7-OH-warfarin) being the 
predominant metabolite: and the 4’-hydroxylation of R-warfarin [6]. 
CYP3A4 regio- and stereo selectively catalyzes the 10-hydroxylation 
of R-warfarin to form (9R; 10S)-10-hydroxywarfarin [(9R; 10S)-
10-OH-warfarin] [7]. Inhibition and induction of CYP2C9- and/
or CYP3A4-mediated warfarin metabolism by co-administered 
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Introduction
Warfarin is the most commonly prescribed oral anticoagulant in 
North America and is indicated for the prophylaxis and treatment 
of a number of serious thromboembolic disorders and complications 
[1]. It elicits an anticoagulant effect by interfering with the synthesis 
of vitamin K-dependent clotting factors in the liver via inhibition of 
the vitamin K epoxies reeducates complex subunit 1 (VKORC1) [2]. 
Warfarin has a narrow therapeutic index and displays considerable 
inter individual variability in dose requirements. To achieve and 
Research Aricle
A Chiral HPLC-MS/MS Method for Simultaneous 
Quantification of Warfarin Enantiomers and its Major 
Hydroxylation Metabolites of CYP2C9 and CYP3A4 in 
Human Plasma
Ju W1, Peng K1, Yang S1, Sun H2, Sampson M2 and 
Wang MZ1*
1Department of Pharmaceutical Chemistry, The 
University of Kansas, USA
2Department of Pharmacy, The University of North 
Carolina at Chapel Hill, USA
*Corresponding author: Wang MZ, Department of 
Pharmaceutical Chemistry, The University of Kansas, 
2095 Constant Ave, Lawrence, KS 66047, USA
Received: August 07, 2014; Accepted: August 20, 




Austin J Anal Pharm Chem 1(2): id1010 (2014)  - Page - 02
Wang MZ Austin Publishing Group
Submit your Manuscript | www.austinpublishinggroup.com
drugs/diets is the main culprit for many clinically important drug 
interactions [1]. Therefore: specific quantification of S-7-OH-warfarin 
(or S-6-OH-warfarin) and (9R; 10S)-10-OH-warfarin in plasma will 
enable phenotypic characterization of CYP2C9 and CYP3A4 catalytic 
activities during clinical drug-drug and drug-diet interaction studies.
Several analytical methods have been reported to achieve 
enantiomeric separation of R- and S-warfarin and/or the 
stereoisomers of clinically important warfarin metabolites. 
Separation and quantification of R-and S-warfarin in human plasma 
has been demonstrated using various chiral High Performance Liquid 
Chromatography (HPLC) columns coupled with detection by UV [8-
12] or tandem mass spectrometry (MS/MS) [13]. However: chiral 
separation and quantification of hydroxylated warfarin metabolites 
has mainly focused on 7-OH-warfarin using a chiral HPLC column 
coupled with UV [14]: fluorescence [15] or MS/MS detection [16]: or 
using capillary zone electrophoresis coupled with UV detection [17]. 
Although specific quantification of the CYP3A4-selective warfarin 
metabolite: (9R; 10S)-10-OH-warfarin: in human plasma using MS/
MS detection has been reported [18]: analytes were separated by 
combining phenyl based reverse phase column and chiral column 
with a complicated sample preparation and a long analytical time 
(17 min). In addition: previously reported analytical methods for the 
warfarin enantiomers in plasma involve either extraction using solid 
phase extraction (SPE) cartridges [8;16;18-20] or phase separation via 
liquid-liquid extraction (LLE) [9-11,13-15]. Extraction of warfarin 
by Protein Precipitation (PPE) has only been used for microsomal 
metabolism studies: where protein concentrations are typically much 
lower (< 2 mg/mL) than in plasma [21,22]. In this study: we aimed 
to 1) develop a chiral HPLC-MS/MS-based method to quantify the 
warfarin enantiomers and two stereo isomeric metabolites: S-7-
OH-warfarin and (9R; 10S)-10-OH-warfarin: in human plasma for 
CYP2C9 and CYP3A4 phenotyping with a short chromatographic 
procedure and 2) determine whether PPE could be used as an 
alternative extraction method for enantiomeric analysis of warfarin 
and its major hydroxylated metabolites in human plasma.
Materials and Methods
Materials
R-warfarin: S-warfarin: racemic warfarin: warfarin metabolites 
(4’-: 6-: 7-: 8- and 10-OH-warfarin): and warfarin-d5 (deuterated 
phenyl ring; used as internal standard [IS]) were purchased from 
Toronto Research Chemicals Inc. (North York: ON: Canada).
Ammonium acetate and dimethylsulfoxide (DMSO) were obtained 
from Sigma-Aldrich (St. Louis: MO: USA). Optima-grade water: 
acetonitrile: methanol: and acetic acid was obtained from Fisher 
Scientific (Pittsburgh: PA: USA). Blank human plasma (collected in 
K2-EDTA tubes) was purchased from Innovative Research (Novi: 
MI: USA). Recombinant human CYP3A4 and CYP2C9 Supersomes™: 
microsomes prepared from baculovirus-infected insect cells 
expressing human CYP enzymes and NADPH-cytochrome P450 
reductase: were purchased from BD Gentlest (Woburn: MA: USA).
Incubation with recombinant CYP3A4 and CYP2C9 
enzymes
The metabolism of R- and S-warfarin by recombinant CYP3A4 
and CYP2C9 was conducted according to a previously published 
protocol [22] with modifications. Briefly: incubation mixtures (50 µL) 
contained R- or S-warfarin (10 µM final concentration): recombinant 
CYP enzymes individually (50 pmol/mL): and 100 mM phosphate 
buffer (pH 7.4) containing 3.3mM MgCl2. Reactions were initiated by 
the addition of NADPH (1 mM final concentration) and allowed to 
proceed for 30 min at 37OC. Control incubations were conducted in 
the absence of NADPH. The reactions were stopped with 400 µL ice-
cold methanol-water (7:1: v/v) and vortexed. Following centrifugation 
to pellet precipitated proteins: the supernatants were dried under 
nitrogen at 50OC for 45 min using a 96-well micro plate evaporator 
(Model SPE Dry 96; Biotage: LLC: Charlotte: NC: USA) and the dried 
sample reconstituted with 250 µL methanol-water (15:85: v/v) prior 
to chiral HPLC-MS/MS analysis.
Preparation of calibration standards and quality controls
Individual stock solutions of R-warfarin: S-warfarin: racemic 
warfarin: warfarin-d5: and each warfarin metabolite (4’-: 6-: 7-: 8- 
and 10-OH-warfarin) were prepared in DMSO. Working standard 
mixtures were prepared by mixing and diluting the stock solutions of 
racemes warfarin:7-OH-warfarin: and 10-OH-warfarin.Calibration 
standards were prepared by spiking 1.0 µL working standard 
mixture into 49 µL blank human plasma to yield the following 
final concentrations: 0.25: 0.5: 1.25: 2.5: 5: 12.5: 25: 50: 125: 250: 
500: 1250: 2500: and 5000 nM for R- and S-warfarin: and 0.05: 0.1: 
0.25: 0.5: 1: 2.5: 5: 10: 25: 50: 100: 250: 500: and 1000 nM for S-7-
OH-warfarin and (9R;10S)-10-OH-warfarin. Quality controls (QCs): 
prepared separately from individual stock solutions: had final plasma 
concentrations of 1.25: 2.5: 50: and 1250 nM for R- and S-warfarin: 
and 0.25: 0.5: 10: and 250 nM for S-7-OH-warfarin and (9R;10S)-10-
OH-warfarin. Calibration standards were prepared in triplicate: while 
QCs in quadruplicate; all were processed as plasma samples before 
chiral HPLC-MS/MS analysis.
Sample preparation and HPLC-MS/MS analysis
Following thawing at room temperature: plasma samples were 
prepared using PPE rather than SPE or LLE. Specifically: plasma 
samples (50 µL) were mixed with 400 µl methanol-water (7:1: v/v) 
containing 30 nM warfarin-d5 as the IS. After vortexing for 10 s: 
the samples were centrifuged at 2250 g for 15 min at 4OC to pellet 
precipitated proteins. The supernatants were evaporated under 
nitrogen at 50OC for 45 min. The dried samples were reconstituted 
with 100 µL methanol-water (15:85: v/v) prior to chiral HPLC-MS/
MS analysis.
HPLC-MS/MS quantification of warfarin and its metabolites 
was performed on a Waters ACQUITY I-Class UPLC (operated at 
normal HPLC pressure) coupled to a Xevo TQ-S triple quadruple 
mass spectrometer equipped with an electro spray ionization 
source (Waters Corporation: Milford: MA: USA). Enantiomeric 
separation of warfarin and its metabolites was achieved with an Astec 
CHIROBIOTIC® V Chiral HPLC column (100 mm × 4.6 mm: 5 μm; 
Supelco: Inc: Bellefonte: PA) protected by an ACQUITY column 
in-line filter (0.2 μm; Waters Corporation). HPLC mobile phase 
(A) consisted of 100% (v/v) water with 5mM ammonium acetate 
(pH4.0: adjusted with acetic acid): while (B) consisted of 100% (v/v) 
acetonitrile. The initial gradient began with 10% B and was held for 
0.2 min. Mobile phase B increased linearly to 40% over 5 min and 
remained at 40% for 1 min. The system was re-equilibrated with 10% 
B for 2 min prior to the next injection. A flow rate of 0.8 mL/min was 
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used throughout the study. The autosampler was set at 6OC and the 
HPLC column heated at 50OC. The sample injection volume was 10 
µL.
The mass spectrometer was operated under negative ion mode for 
multiple reaction monitoring (MRM) of warfarin and its metabolites. 
Typical instrument conditions were: capillary voltage: 0.50 kV; source 
offset: 50 V; desolation temperature: 500OC; desolation gas flow: 1000 
L/h; cone gas flow: 150 L/h; nebulizer gas flow: 7.0 bar; and collision 
gas flow: 0.15 ml/min. Analyze-specific instrument parameters (i.e.: 
collision energy: capillary voltage: cone voltage) were optimized prior 
to analysis using the Intel Start™ auto-tune with infusion of analyze 
standards. The specific MRM transitions used for quantification were 
m/z 307.1 →161.0 for warfarin: m/z 312.2→ 255.1 for warfarin-d5: m/
z323. 1→177.0 for 6-: 7- and 8-OH-warfarin: and m/z 323.1→ 250.3 
for 10-OH-warfarin. Peak area ratios of analyte vs. IS were used to 
generate calibration curves and calculate analyte concentrations in 
plasma samples.
Method validation
Method selectivity was investigated by comparing HPLC-MS/MS 
chromatograms from blank human plasma and plasma spiked with 
standards at the Lower Limit of Quantification (LLOQ). To ensure 
MRM transitions for warfarin and 6-: 7-: 8-: and 10-OH-warfarin 
did not cross-detect 4’-OH-warfarin: chromatograms from plasma 
spiked with 4’-OH-warfarin (200 nM final concentration) also were 
compared.
The intra-day accuracy and precision of the method were 
determined by replicate analysis (n = 4) of the QCs on the same day. 
The inter-day accuracy and precision were determined by replicate 
analysis of the QC son three separate days. Accuracy (%) was defined 
as the closeness of the average QC concentrations determined by the 
method to the true concentrations. Precision (Coefficient of Variation 
[CV]; %) was defined as the spread of the individual measures of 
multiple QC preparations.
The extraction recovery was determined by comparing peak 
area ratios of analyte vs. IS from QC samples that were spiked with 
analyte before extraction to ratios from blank plasma extracts spiked 
with known amounts of pure analyte post-extraction (represents 
100% recovery). The extraction recovery was examined at three QC 
concentrations (2.5: 50: and 1250 nM for R- and S-warfarin; 0.5: 10: 
and 250 nM for S-7-OH-warfarin and (9R;10S)-10-OH-warfarin) 
with quadruplicate samples at each concentration.
Matrix effects during MS/MS analysis were evaluated by 
comparing peak areas of analyte from blank plasma extracts spiked 
with known amounts of pure analyte to peak areas from samples 
prepared in the reconstitution solvent (i.e.: methanol-water [15:85: 
v/v]) with known amounts of pure analyte. The matrix effects also 
were examined at three QC concentrations (2.5: 50: and 1250 nM 
for R- and S-warfarin; 0.5: 10: and 250 nM for S-7-OH-warfarin 
and (9R; 10S)-10-OH-warfarin) with quadruplicate samples at each 
concentration. Results were expressed as % signal remaining relative 
to standards in the reconstitution solvent: which represents100% 
signal remaining.
Freeze-thaw stability was evaluated by exposing QCs to three 
freezing (-80°C) and thawing (room temperature) cycles before 
sample preparation. The thermal stability was evaluated by comparing 
peak areas of standards in methanol-water (15:85: v/v) incubated at 
50OC for 50 min (temperature and time needed during drying) to 
those incubated at 4OC for the same period of time. Sample stability 
in the autosampler was evaluated by repeat-analysis of the same QCs 
stored in a thermostatted autosampler (6OC) for 24 h.
The Limit of Detection (LOD) was defined as the lowest 
concentration of calibration standard that had a signal-to-noise ratio 
(S/N) greater than 10. The LLOQ was defined as 5 times the LOD with 
an accuracy of 80-120%: and an imprecision of ≤20%.
Analysis of human plasma samples from a clinical study
Blood samples were obtained from a healthy volunteer who 
participated in a clinical drug-drug interaction study involving 
warfarin as the victim drug. The human subject received placebo as 
the perpetrating drug and a single oral dose of 10 mg warfarin the 
morning of the study following an overnight fast. Venous blood (5 
ml) was collected in K2-EDTAVacutainer® tubes (BD Biosciences: 
Franklin Lakes: NJ: USA) via an intravenous line at 0: 0.5: 1: 1.5: 2: 3: 
4: 6: 8: 10: 12: 24: 36: 48: 60: 72: 96: 120: 144: and 168 h post-warfarin 
administration. Within 1 h following collection: blood samples 
were centrifuged (3000 rpm at 4OC for 10 min) and the resulting 
plasma samples transferred to pre-labeled cry tubes for storage at 
-80OC until analysis. The clinical study (Clinical Trials.gov registry 
number: NCT01250535) was approved by the Institutional Review 
Board of the University of North Carolina at Chapel Hill (Chapel 
Hill: NC: USA). The area under the plasma concentration–time 
curve (AUC): terminal elimination half-life (t1/2): maximum plasma 
drug concentration (C max): and time to reach C max (T max) were 
calculated using the trapezoidal rule–extrapolation method and non 
compartmental analysis (Phoenix Win Nonlin version 6.3; Pharsight: 
Mountain View: CA: USA).
Figure 1: Extracted ion chromatograms of individual warfarin and 
hydroxylated warfarin standards (200 nM) prepared in blank human plasma. 
The monitored MRM transitions and signal intensity for the most intense peak 
are shown in the upper-left and upper-right corners of each chromatogram, 
respectively. The chemical structure of each analyte also is shown with the 
postulated fragmentation and fragment mass. * denotes a chiral center; # 
denotes the postulated stereochemical assignment.
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Results and Discussion
HPLC-MS/MS analysis and enantiomeric separation
Enantiomeric separation of warfarin and warfarin-d5 (as IS) 
was achieved using a chiral HPLC column. The extracted ion 
chromatograms showed that both racemic warfarin and warfarin-d5 
standards produced two well-resolved peaks at 4.44 and 4.80 min 
for warfarin (Figure 1A): and 4.43 and 4.78 min for warfarin-d5 
(Figure 1B). These peaks are distinguishable from the hydroxylated 
warfarin metabolites due to their characteristic MRM transitions. 
Using synthetic optically pure R- and S-warfarin standards: it was 
determined that R-warfarin eluted at 4.44 min and S-warfarin at 4.80 
min (data not shown). Due to the stereochemical similarity between 
warfarin and warfarin-d5 (deuterated phenyl ring; Figures 1A and 
1B): it can be postulated that R-warfarin-d5 eluted at 4.43 min and 
S-warfarin-d5 at 4.78 min. Subsequently: R-warfarin-d5served as the 
IS for quantification of R-warfarin and (9R; 10S)-10-OH-warfarin: 
while S-warfarin-d5 was used as the IS for quantification of S-warfarin 
and S-7-OH-warfarin.
To determine CYP2C9 and CYP3A4 phenotypes: it is necessary 
to measure the formation of S-7-OH-warfarin (and/or S-6-OH-
warfarin) and (9R; 10S)-10-OH-warfarin: respectively. Since 10-OH-
warfarin can be distinguished from the hydroxylated benzopyran 
metabolites (i.e.: 6-: 7-: and 8-OH-warfarin) via its characteristic 
MRM transition (m/z 323.1→250.3): chromatographic separation 
of these hydroxylation metabolites is not necessary for HPLC-MS/
MS quantification of 10-OH-warfarin. However: 10-OH-warfarin 
contains two chiral centers (Figure 1c): which results in four possible 
stereoisomers. The stereochemistry of the10-OH-warfarin standard 
used in this study was not available from the vendor. Upon chiral 
separation and HPLC-MS/MS analysis: the 10-OH-warfarin standard 
produced two well-resolved peaks at 3.72 and 4.25 min (Figure 1C) or 
at 3.39 and 3.95 min (Figure 3A) using a same column of a different 
batch: corresponding to two of the four possible stereoisomers. It 
is known that CYP3A4 preferentially catalyzes the formation of 
(9R; 10S)-10-OH-warfarin from R-warfarin and (9S; 10R)-10-OH-
warfarin from S-warfarin [6,7]. When R-warfarin was incubated with 
recombinant human CYP3A4: the predominant 10-hydroxylation 
metabolite co-eluted with the 3.39-min peak: confirming the identity 
of the 3.39-min peak as (9R; 10S)-10-OH-warfarin (Figure 3B). 
When S-warfarin was incubated with CYP3A4: the predominant 
10-hydroxylation metabolite co-eluted with the 3.95-min peak: 
confirming the identity of the 3.95-min peak as (9S; 10R)-10-OH-
warfarin (Figure 3B): the enantiomeric stereoisomer of (9R; 10S)-
10-OH-warfarin. This analysis suggests that the 10-OH-warfarin 
standard used in this study was a racemic mixture of (9R; 10S)-10-
OH-warfarin and (9S; 10R)-10-OH-warfarin. Hence it is reasonable 
to assume they had equal concentration in the racemic mixture: 
which allowed us to quantify (9R; 10S)-10-OH-warfarin in plasma 
samples (Figure 3C).
To ensure specificity: enantiomeric separation of S-7-and S-6-
OH-warfarin from the other hydroxylated benzopyran metabolites 
(i.e.: R-7-OH-warfarin: R-6-OH-warfarin: and 8-OH-warfarin) 
should be demonstrated because all of these metabolites have the 
same MRM transition (m/z 323.1→177.0): thus making them 
indistinguishable by MS/MS analysis alone. The extracted ion 
chromatograms for individual standards of 7-: 6-: and 8-OH-warfarin 
is shown in Figures 1D‒F: demonstrating that the enantiomeric pairs 
of these hydroxylated benzopyran metabolites were separated from 
each other. The 7-OH-warfarin standard eluted at 4.14 and 4.61 min 
(Figure 1D). To determine which peak corresponded to the S-7-OH-
warfarin metabolite: S-warfarin was incubated with recombinant 
human CYP2C9: as CYP2C9 preferentially catalyzes the formation 
of S-7-OH-warfarin [23]. Results indicated that S-7-OH-warfarin 
Figure 2: Extracted ion chromatograms of warfarin and its hydroxylation 
metabolites present in a human subject plasma sample obtained 36 h post-
warfarin administration. (A) Chiral separation of S-7- from S-6-OH-warfarin 
was dependent upon the batch quality of the chiral HPLC column used. (B) 
(9R; 10S)-10-OH-warfarin was the predominant 10-OH-warfarin metabolite. 
The monitored MRM transitions and signal intensity for the most intense peak 
are shown in the upper-left and upper-right corners of each chromatogram, 
respectively.
Figure 3: Extracted ion chromatograms of 10-OH-warfarin and its 
hydroxylation metabolites after 30 min incubation with recombinant human 
CYP3A4. (A) 10-OH-warfarin standard. (B) R-warfarin was used as substrate. 
(C) S-warfarin was used as substrate. The monitored MRM transitions and 
signal intensity for the most intense peak are shown in the upper-left and 
upper-right corners of each chromatogram, respectively.
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eluted at 4.61 min and R-7-OH-warfarin at 4.14 min (data not 
shown). Based on the observed elution order of warfarin and 7-OH-
warfarin enantiomers (i.e.: R proceeds S): it can be postulated that 
R-6- and R-8-OH-warfarin co-elute at 4.06 min: while S-6- and S-8-
OH-warfarin elute at 4.49 and 4.31 min: respectively (Figure 1E, 1F). 
Due to minimal HPLC separation of the hydroxylated benzopyran 
metabolites of R-warfarin: they are expected to co-elute if present 
in human plasma samples when analyzed using our method. 
Using a longer HPLC gradient (18 min): Zuo et al. [16] achieved a 
partial separation of these R-warfarin metabolites. However: since 
quantification of these metabolites was not the goal of our study: 
separation using the longer HPLC gradient was not attempted. The 
hydroxylated benzopyran metabolites of S-warfarin (i.e.: S-6-: S-7- 
and S-8-OH-warfarin) eluted at 4.49: 4.61: and 4.31 min (Figures 
1D-F). However: S-6- and S-7-OH-warfarin were only partially 
separated. The extent of separation was found to be dependent upon 
the batch quality of the chiral HPLC column used (Figure 2A). As 
such: the chiral column with the best separation was used to analyze 
clinical plasma samples so that S-7-OH-warfarin could be specifically 
quantified.
Calibration standards: accuracy and precision
Warfarin and 7-OH-warfarin used to prepare calibration 
standards were racemic mixtures of R and S stereoisomers: and 
10-OH-warfarin has been shown to be a racemic mixture of (9R; 
10S)-10-OH-warfarin and (9S; 10R)-10-OH-warfarin. Calibration 
standards for R-warfarin: S-warfarin: S-7-OH-warfarin and (9R; 10S)-
10-OH-warfarin were prepared by spiking blank human plasma with 
working standard mixtures. These calibration standards were then 
processed in a similar manner as clinical plasma samples: described 
in Section 2.4 “Sample preparation and HPLC-MS/MS analysis” 
under Section 2 “Materials and Methods”. The calibration range: 
LOD: S/N at LOD: representative calibration curves: and coefficient 
of determination is summarized in Table 1. The LLOQs obtained by 
this PPE-based method (using only 50 μl plasma) were much lower 
(~10 to 30-fold) than those using an SPE-based HPLC-MS/MS 
quantification method(using 200 μL plasma) [16] (Table 2): largely 
due to the more sensitive triple quadrupole MS instrument used in 
the current study. The enhanced assay sensitivity and calibration 
range will be essential for studies with limited sample availability (e.g.: 
capillary micro sampling [24]).
The intra-day accuracy and precision (CV) of QC samples at low: 
medium and high concentrations were 87.0 to 100.5% and 0.7 to 
6.0% (Table 3). The inter-day accuracy and precision of QC samples 
were 92.3to 99.5% and 0.4 to 4.9% (Table 3). These values are well 
within the criteria of 15% bias and 15% CV provided in the US FDA 
guidance for bio analytical method validation [25].
Extraction recovery: matrix effect and stability
One goal of this study was to simplify the warfarin extraction 
procedure: preferably avoiding SPE. PPE extraction recoveries of the 
four analytes in QC plasma samples are summarized in Table 3.They 
ranged from 82.9 to 95.6% and demonstrated reproducibility (SD < 
8.8%). The recovery achieved with PPE is similar to or greater than 
that obtained with SPE (>80%) [16] or LLE (>73.8%) [14]. Minimal 
matrix effects were observed for R-warfarin: S-warfarin and S-7-
OH-warfarin (Table 4): which all eluted later than (9R; 10S)-10-
OH-warfarin (Figure 1). Significant matrix effects were observed for 
(9R; 10S)-10-OH-warfarin (~50% signal suppression; Table 4): but 
the matrix effects were quite reproducible (CV < 5.5%). Thus: it was 
important to prepare calibration standards in blank human plasma to 
mimic the matrix effects of human plasma samples.
The thermal stability of warfarin and its hydroxylated metabolites 
were evaluated at 50°C for 50 min: which are the temperature and 
time required to dry down PPE-extracted plasma samples. All four 
analytes were determined to be thermally stable with the percent 
remaining ranging from 93.7 to 101.4% (Table 5). The analytes also 
were stable after three freeze-thaw cycles with the percent remaining 
ranging from 96.9 to 113% (Table 5).
Application to human plasma sample analytes
The validated PPE-based chiral HPLC–MS/MS method was 
applied for simultaneous quantification of R-warfarin: S-warfarin: 
S-7-OH-warfarin: and (9R; 10S)-10-OH-warfarin in human plasma 
samples obtained from a clinical drug-drug interaction study involving 
healthy human subjects. Representative extracted ion chromatograms 
of warfarin: warfarin-d5: 7-OH-warfarin: and 10-OH-warfarin for a 
plasma sample collected 36 h post-warfarin administration are shown 
in Figure 2B. The plasma concentration-time profiles of R-warfarin: 
S-warfarin: S-7-OH-warfarin: and (9R;10S)-10-OH-warfarin were 
Figure 4: Plasma concentration-time profiles of R- and S-warfarin (A), as well 
as S-7-OH-warfarin and (9R; 10S) -10-OH-warfarin (B), for a human subject 
that received 10 mg of warfarin orally.
Compound Calibration Rangea S/N at LOD Calibration Curveb COD (R2)b
R-warfarin 0.25–5000 nM ≥13 -0.0000139022•X2 + 0.562725•X-0.0504177 0.99949
S-warfarin 0.25–5000 nM ≥12 -0.0000138943•X2 + 0.564179•X-0.0584107 0.99955
S-7-OH-warfarin 0.1–1000 nM ≥5.4 0.0000258637•X2 + 0.258581•X-0.00957948 0.99967
(9R;10S)-10-OH-warfarin 0.1–1000 nM ≥18 0.000118394•X2 + 0.6412•X-0.0203311 0.99972
Table 1: Calibration standards for warfarin enantiomers, S-7-OH-warfarin, and (9R; 10S)-10-OH-warfarin.
aCalibration range: LOD-ULOQ
bRepresentative calibration curves and coefficient of determination
S/N: Signal-to-Noise Ratio; LOD: Limit of Detection; ULOQ: Upper Limit of Quantification; COD: Coefficient of Determination
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Reported Assays Analytes Quantified Extraction(% Recovery)
Analysis 
Time Dynamic Range LLOQ
Zuo et al., 2010 [16]
warfarin enantiomers, stereoisomers of 7-OH-
warfarin, and monohydroxylated warfarin 
metabolites  (4-, 6-, 8-, and 10-OH-warfarins)
mixed-mode cation-
exchange cartridge  
(> 87%)
17 min
16.3–4890 nM (5–1500 
ng/mL) for warfarin 
enantiomers  
244–586 nM (75–180 ng/
mL) for stereoisomers of 
7-OH-warfarin
16.3 nM (5 ng/mL) for 
warfarin enantiomers and 
stereoisomers of 7-OH-
warfarin 
0.2 mL of plasma
Jones et al., 2011 
[18]
warfarin enantiomers and monohydroxylated 
warfarin metabolites (4-, 6-, 7-, 8-, and 10-OH-
warfarins)
PP by cold 
acetonitrile with 
0.2% formic acid 
(recovery not 
reported)
17 min 2–1000 nM for all analytes 10 nM for all analytes 0.05 mL of plasma
Wu et al. (reported 
herein)
warfarin enantiomers, stereoisomers of 7- and 
10-OH-warfarin
PP by methanol-
water [7:1, v/v] 
(83–97%)
6 min
0.25–5000 nM for warfarin 
enantiomers  
0.1–1000 nM for S-7- and 
(9R;10S)-10-OH-warfarin
1.25 nM for warfarin 
enantiomers   
0.5 nM for S-7- and (9R;10S)-
10-OH-warfarin 
0.05 mL of plasma
Table 2: Comparison of chiral LC-MS/MS analytical assays for warfarin and its hydroxylated metabolites formed by CYP2C9 and CYP3A4.
LLOQ: Lower Limit of Quantification.
Compound QC Concentration (nM)
Intra-day Inter-day
Accuracy (%) Precision (%) Accuracy (%) Precision (%)
R-Warfarin 2.5 94.8 2.2 93.9 0.7
50 99.2 2.2 97.2 1.8
1250 98.5 1.0 98.8 1.1
S-Warfarin 2.5 95.1 1.4 94.1 1.0
50 99.7 2.3 98.1 2.0
1250 98.9 0.9 99.4 0.4
S-7-OH-warfarin 0.5 87.0 6.0 92.9 4.5
10 89.6 1.4 92.3 2.0
250 100.5 1.6 99.5 0.9
(9R;10S)-10-OH-warfarin
0.5 93.2 3.8 96 2.9
10 93.3 1.4 96.8 2.9
250 92.3 0.7 99.2 4.9
Table 3: Intra- and inter-day accuracy and precision for warfarin enantiomers, S-7-OH-warfarin, and (9R;10S)-10-OH-warfarin.
Table 4: Extraction recovery and matrix effect for warfarin enantiomers, S-7-OH-warfarin, and (9R; 10S)-10-OH-warfarin.
PPE: Protein-Precipitation Extraction; SD: Standard Deviation.
Compound QC Concentration (nM)
PPE Extraction Matrix Effect
Recovery (%) SD (%) Remaining Signal (%) SD (%)
R-Warfarin 2.5 94.4 6.7 96.7 3.4
50 86.7 3.6 95.2 2.1
1250 90.2 0.7 96.5 1.0
S-Warfarin 2.5 91.8 7.4 98.8 2.6
50 86.6 2.9 100.6 2.3
1250 94.4 5.5 100.5 0.7
S-7-OH-warfarin 0.5 87.7 4.9 89.8 5.0
10 84.1 1.9 83.5 3.3
250 87.5 6.9 81.4 1.2
(9R;10S)-10-OH-warfarin 0.5 82.9 8.8 49.2 2.7
10 88.2 3.3 52.2 1.6
250 95.6 2.1 50.4 0.7
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Compound QC Concentration (nM)
Thermal Stability Freeze-Thaw Stability
Remaining (%) SD(%) Remaining (%)
SD
(%)
R-Warfarin 2.5 98.0 3.4 100.9 1.3
50 100.6 1.7 102.9 1.3
1250 98.4 1.6 101.9 2.5
S-Warfarin 2.5 98.6 3.2 100.5 1.2
50 101.4 0.9 101.6 1.2
1250 98.7 1.5 100.8 2.8
S-7-OH-warfarin 0.5 99.6 6.4 113.0 11.2
10 93.7 7.4 105.9 4.0
250 97.6 1.2 112.9 4.2
(9R;10S)-10-OH-warfarin
0.5 97.1 3.0 99.0 8.2
10 100.0 1.6 102.2 1.3
250 98.2 2.2 96.9 2.9
Table 5:  Thermal and freeze-thaw stability for warfarin enantiomers, S-7-OH-warfarin, and (9R; 10S)-10-OH-warfarin.
SD: Standard Deviation
Outcomes Units R-warfarin S-warfarin S-7-OH-warfarin (9R;10S)-10-OH-warfarin
Cmax nM 1,497 1,552 105 24
Tmax h 1 1 36 72
AUClast nM•h 68,800 39,500 5,100 3,180
AUC0→∞ nM•h 73,800 40,800 5,270 4,470
t1/2 h 44 35 35 75
Table 6: Pharmacokinetics of warfarin enantiomers, S-7-OH-warfarin and (9R; 10S)-10-OH-warfarin in a human subject.
Abbreviations: C max: Maximum Concentration; T max: Time to reach; AUC last: Area under the curve from time zero to the last measurable concentration; AUC0-∞: area 
under the curve from time zero to infinite time; t1/2: terminal elimination half-life
plotted for a human subject that received 10 mg warfarin orally the 
morning of the study and was monitored for 7 days post-warfarin 
administration (Figure 4A, 4B). Pharmacokinetic measurements are 
summarized in Table 6. These values are in agreement with those 
previously reported for warfarin enantiomers [26].
Conclusion
A simple PPE-based: highly sensitive chiral HPLC–MS/MS 
analytical method with short retention time has been developed 
and validated for simultaneous enantiomeric quantification of 
R-warfarin: S-warfarin: S-7-OH-warfarin: and (9R; 10S)-10-OH-
warfarin in human plasma. This method is expected to be more time-
and cost-effective than SPE- or LLE-based methods. Furthermore: 
the outstanding sensitivity afforded by the combined high extraction 
recovery: low matrix suppression effect: and sensitive triple quadruple 
MS instrument will enable studies with limited sample availability 
(e.g.: capillary microsampling). Specific quantification of S-7-OH-
warfarin and (9R; 10S)-10-OH-warfarin will enable phenotypic 
characterization of CYP2C9 and CYP3A4 activities for drug-drug 
and drug-diet interaction studies involving these two CYP enzymes.
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